Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 606

1.

2018 Nobel Prize in physiology or medicine.

Smyth MJ, Teng MW.

Clin Transl Immunology. 2018 Oct 24;7(10):e1041. doi: 10.1002/cti2.1041. eCollection 2018. No abstract available.

2.

Bone marrow transplantation generates T cell-dependent control of myeloma in mice.

Vuckovic S, Minnie SA, Smith D, Gartlan KH, Watkins TS, Markey KA, Mukhopadhyay P, Guillerey C, Kuns RD, Locke KR, Pritchard AL, Johansson PA, Varelias A, Zhang P, Huntington ND, Waddell N, Chesi M, Miles JJ, Smyth MJ, Hill GR.

J Clin Invest. 2018 Nov 19. pii: 98888. doi: 10.1172/JCI98888. [Epub ahead of print]

3.

Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy.

Ahern E, Smyth MJ, Dougall WC, Teng MWL.

Nat Rev Clin Oncol. 2018 Nov;15(11):676-693. doi: 10.1038/s41571-018-0095-y. Review.

PMID:
30232468
4.

The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells.

Lepletier A, Lutzky VP, Mittal D, Stannard K, Watkins TS, Ratnatunga CN, Smith C, McGuire HM, Kemp RA, Mukhopadhyay P, Waddell N, Smyth MJ, Dougall WC, Miles JJ.

Immunol Cell Biol. 2018 Sep 17. doi: 10.1111/imcb.12205. [Epub ahead of print]

PMID:
30222899
5.

Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade.

Mittal D, Vijayan D, Smyth MJ.

Cancer Discov. 2018 Sep;8(9):1066-1068. doi: 10.1158/2159-8290.CD-18-0798.

PMID:
30181171
6.

Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade.

Minnie SA, Kuns RD, Gartlan KH, Zhang P, Wilkinson AN, Samson L, Guillerey C, Engwerda C, MacDonald KPA, Smyth MJ, Markey KA, Vuckovic S, Hill GR.

Blood. 2018 Oct 18;132(16):1675-1688. doi: 10.1182/blood-2018-01-825240. Epub 2018 Aug 28.

PMID:
30154111
7.

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma.

Guillerey C, Harjunpää H, Carrié N, Kassem S, Teo T, Miles K, Krumeich S, Weulersse M, Cuisinier M, Stannard K, Yu Y, Minnie SA, Hill GR, Dougall WC, Avet-Loiseau H, Teng MWL, Nakamura K, Martinet L, Smyth MJ.

Blood. 2018 Oct 18;132(16):1689-1694. doi: 10.1182/blood-2018-01-825265. Epub 2018 Jul 9.

PMID:
29986909
8.

Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23.

Yan J, Allen S, Vijayan D, Li XY, Harjunpää H, Takeda K, Liu J, Cua DJ, Smyth MJ, Teng MWL.

Cancer Immunol Res. 2018 Aug;6(8):978-987. doi: 10.1158/2326-6066.CIR-18-0011. Epub 2018 Jun 19.

PMID:
29921599
9.

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Harjunpää H, Blake SJ, Ahern E, Allen S, Liu J, Yan J, Lutzky V, Takeda K, Aguilera AR, Guillerey C, Mittal D, Li XY, Dougall WC, Smyth MJ, Teng MWL.

Oncoimmunology. 2018 Mar 26;7(7):e1445949. doi: 10.1080/2162402X.2018.1445949. eCollection 2018.

PMID:
29900061
10.

TGFβ shuts the door on T cells.

Bald T, Smyth MJ.

Br J Cancer. 2018 Jul;119(1):1-3. doi: 10.1038/s41416-018-0122-x. Epub 2018 Jun 14.

PMID:
29899392
11.

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.

Ahern E, Harjunpää H, O'Donnell JS, Allen S, Dougall WC, Teng MWL, Smyth MJ.

Oncoimmunology. 2018 Feb 14;7(6):e1431088. doi: 10.1080/2162402X.2018.1431088. eCollection 2018.

PMID:
29872559
12.

Aberrant erythropoiesis fuels tumor growth.

Nakamura K, Smyth MJ.

Cell Res. 2018 Jun;28(6):611-612. doi: 10.1038/s41422-018-0047-1. No abstract available.

PMID:
29844580
13.

Remote physiological monitoring in an austere environment: a future for battlefield care provision?

Smyth MJ, Round JA, Mellor AJ.

J R Army Med Corps. 2018 Nov;164(6):410-413. doi: 10.1136/jramc-2017-000905. Epub 2018 May 14.

PMID:
29764915
14.

CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.

Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ.

J Clin Invest. 2018 Jun 1;128(6):2613-2625. doi: 10.1172/JCI98769. Epub 2018 May 14.

15.

CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

Roman Aguilera A, Lutzky VP, Mittal D, Li XY, Stannard K, Takeda K, Bernhardt G, Teng MWL, Dougall WC, Smyth MJ.

Oncoimmunology. 2018 Feb 1;7(5):e1424677. doi: 10.1080/2162402X.2018.1424677. eCollection 2018.

PMID:
29721390
16.

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.

Nakamura K, Kassem S, Cleynen A, Chrétien ML, Guillerey C, Putz EM, Bald T, Förster I, Vuckovic S, Hill GR, Masters SL, Chesi M, Bergsagel PL, Avet-Loiseau H, Martinet L, Smyth MJ.

Cancer Cell. 2018 Apr 9;33(4):634-648.e5. doi: 10.1016/j.ccell.2018.02.007.

PMID:
29551594
17.

Rapid loss of group 1 innate lymphoid cells during blood stage Plasmodium infection.

Ng SS, Souza-Fonseca-Guimaraes F, Rivera FL, Amante FH, Kumar R, Gao Y, Sheel M, Beattie L, Montes de Oca M, Guillerey C, Edwards CL, Faleiro RJ, Frame T, Bunn PT, Vivier E, Godfrey DI, Pellicci DG, Lopez JA, Andrews KT, Huntington ND, Smyth MJ, McCarthy J, Engwerda CR.

Clin Transl Immunology. 2018 Jan 12;7(1):e1003. doi: 10.1002/cti2.1003. eCollection 2018.

18.

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.

Mastaglio S, Wong E, Perera T, Ripley J, Blombery P, Smyth MJ, Koldej R, Ritchie D.

Blood Adv. 2018 Feb 27;2(4):335-346. doi: 10.1182/bloodadvances.2017015230.

19.

Flt-3L Expansion of Recipient CD8α+ Dendritic Cells Deletes Alloreactive Donor T Cells and Represents an Alternative to Posttransplant Cyclophosphamide for the Prevention of GVHD.

Markey KA, Kuns RD, Browne DJ, Gartlan KH, Robb RJ, Martins JP, Henden AS, Minnie SA, Cheong M, Koyama M, Smyth MJ, Steptoe RJ, Belz GT, Brocker T, Degli-Esposti MA, Lane SW, Hill GR.

Clin Cancer Res. 2018 Apr 1;24(7):1604-1616. doi: 10.1158/1078-0432.CCR-17-2148. Epub 2018 Jan 24.

PMID:
29367429
20.

Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT.

Gartlan KH, Varelias A, Koyama M, Robb RJ, Markey KA, Chang K, Wilkinson AN, Smith D, Ullah MA, Kuns RD, Raffelt NC, Olver SD, Lineburg KE, Teal BE, Cheong M, Teng MWL, Smyth MJ, Tey SK, MacDonald KPA, Hill GR.

Blood Adv. 2017 Jan 26;1(6):341-351. doi: 10.1182/bloodadvances.2016002980. eCollection 2017 Feb 14.

21.

A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.

Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ.

Cancer Res. 2018 Feb 15;78(4):1003-1016. doi: 10.1158/0008-5472.CAN-17-2826. Epub 2017 Dec 11.

PMID:
29229601
22.

Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.

Brooks J, Fleischmann-Mundt B, Woller N, Niemann J, Ribback S, Peters K, Demir IE, Armbrecht N, Ceyhan GO, Manns MP, Wirth TC, Kubicka S, Bernhardt G, Smyth MJ, Calvisi DF, Gürlevik E, Kühnel F.

Cancer Res. 2018 Jan 15;78(2):475-488. doi: 10.1158/0008-5472.CAN-17-2415. Epub 2017 Nov 27.

PMID:
29180478
23.

Targeting immunosuppressive adenosine in cancer.

Vijayan D, Young A, Teng MWL, Smyth MJ.

Nat Rev Cancer. 2017 Nov 22;17(12):765. doi: 10.1038/nrc.2017.110. No abstract available.

PMID:
29162946
24.

Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis.

Mittal D, Vijayan D, Putz EM, Aguilera AR, Markey KA, Straube J, Kazakoff S, Nutt SL, Takeda K, Hill GR, Waddell N, Smyth MJ.

Cancer Immunol Res. 2017 Dec;5(12):1098-1108. doi: 10.1158/2326-6066.CIR-17-0341. Epub 2017 Oct 25.

PMID:
29070650
25.

Targeting immunosuppressive adenosine in cancer.

Vijayan D, Young A, Teng MWL, Smyth MJ.

Nat Rev Cancer. 2017 Dec;17(12):709-724. doi: 10.1038/nrc.2017.86. Epub 2017 Oct 23. Review. Erratum in: Nat Rev Cancer. 2017 Nov 22;17 (12 ):765.

PMID:
29059149
26.

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.

Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M.

Immunity. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012.

27.

Cytokine-driven role of Srebps in killer cell metabolism.

Guillerey C, Smyth MJ.

Nat Immunol. 2017 Oct 18;18(11):1183-1184. doi: 10.1038/ni.3855. No abstract available.

PMID:
29044236
28.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

29.

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, José V, Pommey S, Delisle V, Loi S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Smyth MJ, Stagg J.

Cancer Res. 2017 Oct 15;77(20):5652-5663. doi: 10.1158/0008-5472.CAN-17-0707. Epub 2017 Aug 30.

30.

Control of Metastasis by NK Cells.

López-Soto A, Gonzalez S, Smyth MJ, Galluzzi L.

Cancer Cell. 2017 Aug 14;32(2):135-154. doi: 10.1016/j.ccell.2017.06.009. Review.

31.

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ.

Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31.

PMID:
28759001
32.

Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Yan J, Smyth MJ, Teng MWL.

Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7). pii: a028530. doi: 10.1101/cshperspect.a028530. Review.

PMID:
28716888
33.

PD1 functions by inhibiting CD28-mediated co-stimulation.

O'Donnell JS, Smyth MJ, Teng MWL.

Clin Transl Immunology. 2017 May 5;6(5):e138. doi: 10.1038/cti.2017.15. eCollection 2017 May. No abstract available.

34.

Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.

Zhao Y, Ting KK, Li J, Cogger VC, Chen J, Johansson-Percival A, Ngiow SF, Holst J, Grau G, Goel S, Muller T, Dejana E, McCaughan G, Smyth MJ, Ganss R, Vadas MA, Gamble JR.

Cancer Res. 2017 Aug 15;77(16):4434-4447. doi: 10.1158/0008-5472.CAN-16-3129. Epub 2017 Jun 27. Erratum in: Cancer Res. 2018 Oct 1;78(19):5718.

35.

MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy.

Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M.

Cancer Res. 2017 Sep 1;77(17):4697-4709. doi: 10.1158/0008-5472.CAN-17-0395. Epub 2017 Jun 26.

36.

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.

Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth MJ.

Cancer Res. 2017 Sep 1;77(17):4684-4696. doi: 10.1158/0008-5472.CAN-17-0393. Epub 2017 Jun 26.

37.

Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases.

Vijayan D, Barkauskas DS, Stannard K, Sult E, Buonpane R, Takeda K, Teng MWL, Sachsenmeier K, Hay C, Smyth MJ.

Oncoimmunology. 2017 Apr 5;6(5):e1312044. doi: 10.1080/2162402X.2017.1312044. eCollection 2017.

38.

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.

Ahern E, Harjunpää H, Barkauskas D, Allen S, Takeda K, Yagita H, Wyld D, Dougall WC, Teng MWL, Smyth MJ.

Clin Cancer Res. 2017 Oct 1;23(19):5789-5801. doi: 10.1158/1078-0432.CCR-17-0606. Epub 2017 Jun 20.

39.

G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis.

Casciello F, Al-Ejeh F, Kelly G, Brennan DJ, Ngiow SF, Young A, Stoll T, Windloch K, Hill MM, Smyth MJ, Gannon F, Lee JS.

Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7077-7082. doi: 10.1073/pnas.1618706114. Epub 2017 Jun 19.

40.

NK cell heparanase controls tumor invasion and immune surveillance.

Putz EM, Mayfosh AJ, Kos K, Barkauskas DS, Nakamura K, Town L, Goodall KJ, Yee DY, Poon IK, Baschuk N, Souza-Fonseca-Guimaraes F, Hulett MD, Smyth MJ.

J Clin Invest. 2017 Jun 30;127(7):2777-2788. doi: 10.1172/JCI92958. Epub 2017 Jun 5.

41.

Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.

Putz EM, Guillerey C, Kos K, Stannard K, Miles K, Delconte RB, Takeda K, Nicholson SE, Huntington ND, Smyth MJ.

Oncoimmunology. 2017 Feb 7;6(2):e1267892. doi: 10.1080/2162402X.2016.1267892. eCollection 2017.

42.

BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies.

Ambalathingal GR, Francis RS, Smyth MJ, Smith C, Khanna R.

Clin Microbiol Rev. 2017 Apr;30(2):503-528. doi: 10.1128/CMR.00074-16. Review.

43.

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

Dougall WC, Kurtulus S, Smyth MJ, Anderson AC.

Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518. Review.

PMID:
28258695
44.

HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors.

Medon M, Vidacs E, Vervoort SJ, Li J, Jenkins MR, Ramsbottom KM, Trapani JA, Smyth MJ, Darcy PK, Atadja PW, Henderson MA, Johnstone RW, Haynes NM.

Cancer Res. 2017 May 15;77(10):2594-2606. doi: 10.1158/0008-5472.CAN-16-2247. Epub 2017 Mar 1.

45.

IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting.

Takeda K, Nakayama M, Hayakawa Y, Kojima Y, Ikeda H, Imai N, Ogasawara K, Okumura K, Thomas DM, Smyth MJ.

Nat Commun. 2017 Feb 24;8:14607. doi: 10.1038/ncomms14607.

46.

Multiple approaches to immunotherapy - the new pillar of cancer treatment.

Smyth MJ.

Immunol Cell Biol. 2017 Apr;95(4):323-324. doi: 10.1038/icb.2017.9. No abstract available.

PMID:
28174425
47.

Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice.

Overman J, Fontaine F, Moustaqil M, Mittal D, Sierecki E, Sacilotto N, Zuegg J, Robertson AA, Holmes K, Salim AA, Mamidyala S, Butler MS, Robinson AS, Lesieur E, Johnston W, Alexandrov K, Black BL, Hogan BM, De Val S, Capon RJ, Carroll JS, Bailey TL, Koopman P, Jauch R, Smyth MJ, Cooper MA, Gambin Y, Francois M.

Elife. 2017 Jan 31;6. pii: e21221. doi: 10.7554/eLife.21221.

48.

Targeting cancer-related inflammation in the era of immunotherapy.

Nakamura K, Smyth MJ.

Immunol Cell Biol. 2017 Apr;95(4):325-332. doi: 10.1038/icb.2016.126. Epub 2017 Jan 10. Review.

PMID:
27999432
49.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

50.

Resistance to PD1/PDL1 checkpoint inhibition.

O'Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ.

Cancer Treat Rev. 2017 Jan;52:71-81. doi: 10.1016/j.ctrv.2016.11.007. Epub 2016 Nov 27. Review.

PMID:
27951441

Supplemental Content

Loading ...
Support Center